AbbVie Inc. Other Comprehensive Income (Loss), before Reclassifications, Net of Tax
AbbVie Inc. (ABBV) reported Other Comprehensive Income (Loss), before Reclassifications, Net of Tax of -$310.00 million for the 6-month period ending 2015-06-30, per its 10-Q filed 2015-08-07.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax · last filed 2015-08-07
- AbbVie Inc. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2015-06-30 was $121.00M.
- AbbVie Inc. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2015-03-31 was -$431.00M.
- AbbVie Inc. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2014-12-31 was -$1.14B, a 327.35% decline year-over-year.
- AbbVie Inc. other comprehensive income (loss), before reclassifications, net of tax for the quarter ending 2014-09-30 was -$536.00M.
- AbbVie Inc. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2014 was -$1.71B, a 448.68% decline from fiscal 2013.
- AbbVie Inc. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2013 was $491.00M.
- AbbVie Inc. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2012 was -$18.00M.
- AbbVie Inc. other comprehensive income (loss), before reclassifications, net of tax for fiscal 2011 was -$300.00M.
| Period end | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 3 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 6 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 9 month | Other Comprehensive Income (Loss), before Reclassifications, Net of Tax 12 month |
|---|---|---|---|---|
| 2015-06-30 | $121.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | -$310.00M 10-Q · filed 2015-08-07 | -$1.45B derived: sum of 3 quarters · filed 2015-08-07 | -$1.99B derived: sum of 4 quarters · filed 2015-08-07 |
| 2015-03-31 | -$431.00M 10-Q · filed 2015-05-08 | -$1.57B derived: sum of 2 quarters · filed 2015-05-08 | -$2.11B derived: sum of 3 quarters · filed 2015-05-08 | -$2.13B derived: sum of 4 quarters · filed 2015-08-07 |
| 2014-12-31 | -$1.14B derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-20 | -$1.68B derived: sum of 2 quarters · filed 2015-02-20 | -$1.70B derived: sum of 3 quarters · filed 2015-08-07 | -$1.71B 10-K · filed 2015-02-20 |
| 2014-09-30 | -$536.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | -$565.00M derived: sum of 2 quarters · filed 2015-08-07 | -$573.00M 10-Q · filed 2014-11-07 | -$72.00M derived: sum of 4 quarters · filed 2015-08-07 |
| 2014-06-30 | -$29.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | -$37.00M 10-Q · filed 2015-08-07 | $464.00M derived: sum of 3 quarters · filed 2015-08-07 | |
| 2014-03-31 | -$8.00M 10-Q · filed 2015-05-08 | $493.00M derived: sum of 2 quarters · filed 2015-05-08 | ||
| 2013-12-31 | $501.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-20 | $491.00M 10-K · filed 2015-02-20 | ||
| 2013-09-30 | -$10.00M 10-Q · filed 2013-11-12 | |||
| 2012-12-31 | -$18.00M 10-K · filed 2015-02-20 | |||
| 2011-12-31 | -$300.00M 10-K · filed 2014-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |